

Central Nervous System Therapeutics Market Will Surpass US\$ 381.27 Billion at 10.5% CAGR Growth From 2025 to 2034

The growing existence of CNS disorders worldwide is a prominent factor driving the central nervous system therapeutics market.

NEW YORK CITY, NY, UNITED STATES, February 21, 2025 /EINPresswire.com/ -- 000 000000

"

These therapeutics involve medicines such as antidepressants and antipsychotics, and other medications such as neuromodulation techniques and behavioral therapies."

Polaris Market Research

Diagnosis of a nervous system disorder is time-consuming. Doctors work with patients to abolish several issues and render a particular diagnosis. They normally include several tests and an assessment of indications. Probable indications include persevering headaches and deprivation of tingling sensations.


https://www.polarismarketresearch.com/industry-analysis/central-nervous-system-therapeutics-market/request-for-

sample?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01

Treatment relies on particular conditions and may often include medicines and supplements, nutritional reinforcement, and spinal manipulation. Conditions such as depression, anxiety, Alzheimer's disease, and multiple sclerosis are being detected more often, causing the growing demand for productive treatments and impacting the central nervous system therapeutics market growth favorably.

The market is continuously developing with several firms struggling to invent and differentiate themselves. Here are some of the leading players in the central nervous system therapeutics market:

- Astra Zeneca
- Biogen
- Eli Lilly and Company
- · Merck & Co., Inc.
- Novartis AG
- Otsuka Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd



Central Nervous System Therapeutics Market

- In May 2024, Teva Pharmaceuticals declared the FDA consent of AUSTEDO XR as a once-daily therapy for tardive dyskinesia and Huntington's disease chorea, promoting four contemporary tablet robustness.
- In May 2024, an absolute global alternative and license agreement was declared between Takeda and AC Immune for the advancement of ACI-24.060, an agile immunotherapy aiming at toxic amyloid beta configurations that cures Alzheimer's disease and probably retarding its advancements.

https://www.polarismarketresearch.com/industry-analysis/central-nervous-system-therapeutics-market/request-for-discount-

pricing?utm source=EIN&utm medium=EIN&utm campaign=EIN&utm id=01

0000'0 0000000 000000 0000000?

administrative reinforcement for drug approvals. Administrative bodies such as the FDA have enhanced their procedures to ease speedier approvals for contemporary cures, especially for grave CNS disorders.

and mental health cases such as Alzheimer's disease, dementia, and depression. For instance, in

2020, the Organization for Economic Co-operation and Development divulged that the allocation of the population aged 65 and above has surged to 17.96%. This, in turn, is having a favorable impact on central nervous system therapeutics market sales.

encouraging governments, establishments, and private investors to fund notably productive cures. For instance, as per the Keshav Desiraju India Mental Health Observatory, the Indian government administered USD 144.46 million in the yearly budget for 2023-2024 to confront mental health-connected illnesses.

https://www.polarismarketresearch.com/industry-analysis/central-nervous-system-therapeutics-market/inquire-before-

buying?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01

□□□□ □□□□□□□: Asia Pacific is anticipated to witness significant growth from 2025 to 2034. This can be attributed to growing government funding in healthcare.

By Disease Outlook

- Neurovascular Diseases
- CNS Trauma
- Mental Health
- Neurodegenerative Diseases
- · Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Huntington's Disease
- Amyotrophic Lateral Sclerosis
- Others
- · Infectious Diseases
- CNS Cancer
- Others

By Drug Class Outlook

- Anesthetics
- Anticonvulsants
- Antiemetics

- CNS Stimulants
- Pain Relievers
- Others

By Distribution Channel Outlook

- Hospital Pharmacies
- · Retail Pharmacies
- Others

$00\ 00000000\ 0000000$

- North America
- o US
- o Canada
- Europe
- o Germany
- o France
- o UK
- o Italy
- o Spain
- o Netherlands
- o Russia
- o Rest of Europe
- Asia Pacific
- o China
- o Japan
- o India
- o Malaysia
- o South Korea
- o Indonesia
- o Australia
- o Rest of Asia Pacific
- · Middle East & Africa
- o Saudi Arabia
- o UAE
- o Israel
- o South Africa
- o Rest of the Middle East & Africa
- · Latin America
- o Mexico

- o Brazil
- o Argentina
- o Rest of Latin America

How much is the central nervous system therapeutics market?

The market size was valued at USD 141.09 billion in 2024 and is projected to grow to USD 381.27 billion by 2034.

Who are the key players in the central nervous system therapeutics market?

A few of the key players in the market are Biogen; Otsuka Pharmaceutical Co., Ltd.; Eli Lilly and Company; Merck & Co., Inc.; Astra Zeneca; Takeda

Pharmaceutical Company Limited; Novartis AG; Teva Pharmaceutical Industries Ltd; Johnson & Johnson, Inc.; and Pfizer Inc.

Based on drug class, which segment is expected to experience significant growth with a high CAGR in the global market?

The CNS stimulants segment is expected to experience significant growth with a high CAGR in the global market.

What are the segments covered in the market?

The segments covered in the market are disease, drug class, and distribution channel.

000000 0000 00000000 00000000:

Speaking Valve Market:

https://www.polarismarketresearch.com/industry-analysis/speaking-valve-market

Bio-Based Polypropylene in Medical Devices Market:

https://www.polarismarketresearch.com/industry-analysis/bio-based-polypropylene-in-medical-devices-market

3D Ultrasound Market:

https://www.polarismarketresearch.com/industry-analysis/3d-ultrasound-market

Sacral Nerve Stimulation Market:

https://www.polarismarketresearch.com/industry-analysis/sacral-nerve-stimulation-market

Central Nervous System Therapeutics Market:

https://www.polarismarketresearch.com/industry-analysis/central-nervous-system-therapeutics-market

Cholesterol Testing Products and Services Market:

https://www.polarismarketresearch.com/industry-analysis/cholesterol-testing-products-andservices-market

Vascular Stent Market:

https://www.polarismarketresearch.com/industry-analysis/vascular-stent-market

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

Likhil G
Polaris Market Research and Consulting
+ +1 929-297-9727
email us here
Visit us on social media:
Facebook
X
LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/788006710

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.